Hollings Headlines // June 2019
Kathy Cole with bike
LOWVELO ambassador pushes MUSC, community to pedal for cancer

 MUSC First Lady Kathy Cole has strong ties to the medical community and hopes to encourage MUSC employees and others who join MUSC teams to get the most out of participating in LOWVELO, a bike ride to raise money for cancer research. Scheduled for Nov. 1 and 2, the ride features three routes, 25-, 50- and 100-mile options, which showcase the scenic landscapes of the Lowcountry.

Best ride across the country: LOWVELO releases routes

LOWVELO is the perfect ride for all fitness levels, providing three ride options; each route showcases the beauty of the Lowcountry.

Lowvelo jersey
T ime to order your jersey!

Every rider who participates in LOWVELO will receive their very own inaugural bike jersey. This small gift is our way of thanking you for supporting Hollings Cancer Center research.

Clinical Highlights
Dr. Abbott and Steven Fee
T-VEC offers promising treatment for melanoma

Steven Fee has gotten used to the drive from Hilton Head to Hollings Cancer Center. For him, it’s a small price to pay for the latest in melanoma treatment that includes an innovative therapy called T-VEC.

Dr. Hudspeth with patient
‘Make it happen’ is the goal of the new medical director of award-winning BMT program

Following in a tradition of excellence set by her predecessor, Michelle Hudspeth, M.D., takes the reins as the medical director of the Blood & Marrow Transplant Program Transplant Program at Hollings Cancer Center at MUSC.

Research Highlights
Tissue imaging
The deep learning dive: How cells regulate division

Combining tissue imaging and artificial intelligence, Hollings Cancer Center researchers probed deeper into how cell division cycles are regulated, in a study released online in the May issue of Cell Reports.

Dr. Rubinstein in Hollings laboratory
NCI awards $3M grant to Hollings immunotherapy team

Researchers received a $3 million grant from the National Cancer Institute to continue work on a novel immunotherapy combination using checkpoint drug nivolumab and the immune stimulation drug ALT-803 to treat patients with lung cancer.

86 Jonathan Lucas Street, Charleston, SC 29425 | Privacy Policy
Connect With Us